Bristol Myers Squibb
CompanyUnited StatesFounded 1989
Bristol Myers Squibb develops 43 assets, the furthest approved (abatacept in Active Polyarticular Juvenile Idiopathic Arthritis). Mostly small molecule and antibody acting on PPARA, DDB1 and CRBN; based in the United States, founded in 1989.
- 43
- Assets
- Furthest stage
- Approved
- 1,084
- Trials
- 421
- Signals
Pipeline
43Binds CD80 and CD86 to block T-cell costimulation and suppress inflammation.
Approved, Protein or enzyme, CD80, CD86, Active Polyarticular Juvenile Idiopathic Arthritis, psoriatic arthritis
Inhibits mutant KRAS G12C, blocking signaling that drives tumor growth.
Approved, Small molecule, KRAS, non-small cell lung cancer, advanced non small cell lung cancer
PPARalpha agonist that modifies plasma lipids.
Approved, Small molecule, PPARA, dyslipidemia (Phase 3), hypertension (Phase 3), Partner
40 more assets
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
64 assets, 228 trials
3 assets, 18 trials
2 assets, 13 trials
1 asset, 31 trials
1 asset, 5 trials
1 asset, 2 trials
In the full profile
- Evidence behind the mechanisms9
- Trials2,609
- Deals7
- Signals20
- Integrity notices1
- Similar companies6
Papers
Adverse Clinical Events in Secondary Stroke Prevention: A Nationwide Cohort Study in Sweden
AHA Scientific Sessions 2026 abstract, Nov 9, 2026
AHA Scientific Sessions 2026 abstract, Nov 7, 2026
ESC Congress 2026 abstract, Oct 26, 2026
Mobile DNA activity differs by mutation in human blood cells
GeroScience, Sep 16, 2026
medRxiv : the preprint server for health sciences, Aug 20, 2026
Loss of a muscle protein mimics age-related changes in mice
Biomolecules, Jul 28, 2026
Multiple sclerosis journal - experimental, translational and clinical, Jul 23, 2026
Post reproductive health, Jul 22, 2026
ITU Tier 1+ #32: Pharmaceuticals (K_pharma)
Zenodo (CERN European Organization for Nuclear Research), May 19, 2026
Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity
Nature genetics, Mar 28, 2026
Dephospho-Uncarboxylated Matrix Gla-Protein Is Associated With Adverse Outcomes in Heart Failure
Circulation. Heart failure, Jan 28, 2026
Nature communications, Jan 23, 2026
American journal of hematology, Jan 19, 2026
Nature aging, Aug 6, 2025
Nature communications, Feb 7, 2025
Sex-dependent differences in hematopoietic stem cell aging and leukemogenic potential
Oncogene, Nov 2, 2024
Atrial Fibrillation Burden on a 14-Day ECG Monitor: Findings From the GUARD-AF Trial Screening Arm
JACC. Clinical electrophysiology, Sep 22, 2024
Journal of the American Heart Association, Aug 31, 2024
Adult stem cell activity in naked mole rats for long-term tissue maintenance
Nature communications, Dec 20, 2023
GeroScience, Apr 20, 2023